Latest Breaking News On - Sharvil patel - Page 18 : comparemela.com

Zydus Gets Nil Observations On USFDA Inspection Receives Nod For Two Drugs

Zydus Gets Nil Observations On USFDA Inspection Receives Nod For Two Drugs
businessworld.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businessworld.in Daily Mail and Mail on Sunday newspapers.

Zydus lifesciencesSharvil patelZydus biotech parkDiclofenac sodiumMisoprostol delayed release tabletsListed drugArthrotec delayed releaseUnited statesManaging director

Zydus receives final approval from the USFDA for Varenicline Tablets

Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration to manufacture and market Varenicline Tablets, 0.5 mg and 1 mg.

United statesSharvil patelDrug administrationZydus lifeciencesZydus lifesciencesLifesciences limitedUnited states foodVarenicline tabletsManaging directorZydus lifeciences limitedZydus lifesciences limited

Zydus Lifesciences gets U S FDA approval for two products

Zydus Lifesciences gets U S FDA approval for two products
thehindu.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindu.com Daily Mail and Mail on Sunday newspapers.

Sharvil patelZydus lifesciencesDrug administrationDiclofenac sodiumMisoprostol delayed release tabletsArthrotec delayed releaseVarenicline tabletsZydus biotech park

Zydus Lifesciences plans to raise R&D spend in FY24 with focus on innovation products

'We are well poised to maintain growth momentum, with India geography likely to hold double-digit growth,' says Sharvil Patel, Managing Director, Zydus Lifesciences

United statesMotilal oswalSharvil patelZydus lifesciencesZydus lifesciences ltdDrug administrationManaging directorRisk evaluationMitigation strategyR amp dHealth stocksPharma stocksPharma companies

Zydus Lifesciences Q4 consolidated net profit dips 25 36% to Rs 296 6 cr

The company, said its board has recommended a final dividend of Rs 6 per equity share of Re 1 each, subject to approval of shareholders at the Annual General Meeting scheduled to be held on August 11, 2023.

Sharvil patelZydus lifesciencesZydus lifesciences ltd onZydus wellness products ltdSentynl therapeutics incLifesciences ltdAnnual general meetingLifesciences managing director sharvil patelZydus lifesciences q4 resultsQ4 results